FDA.reportPublic FDA data

donidalorsen 80 MG (equivalent to donidalorsen sodium 84 MG) per 0.8 ML Auto-Injector

RxCUI
2724447
RxNorm name
donidalorsen 80 MG (equivalent to donidalorsen sodium 84 MG) per 0.8 ML Auto-Injector
Display name
donidalorsen 80 MG (equivalent to donidalorsen sodium 84 MG) per 0.8 ML Auto-Injector
Full name
donidalorsen 80 MG (equivalent to donidalorsen sodium 84 MG) per 0.8 ML Auto-Injector
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:38:55

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
DAWNZERADONIDALORSENIonis Pharmaceuticals Inc.3ff501e0-f75f-07da-e063-6294a90a0cb72025-09-24Warnings, Adverse reactionsExact identifier
rxcui: 2724447

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
3ff501e0-f75f-07da-e063-6294a90a0cb7donidalorsen 80 MG in 0.8 ML Auto-Injector [PSN] · 0.8 ML donidalorsen 100 MG/ML Auto-Injector [SCD] · donidalorsen 80 MG (equivalent to donidalorsen sodium 84 MG) per 0.8 ML Auto-Injector [SY]31These highlights do not include all the information needed to use DAWNZERA™ (donidalorsen) safely and effectively. See full prescribing information for DAWNZERA. DAWNZERA™ (donidalorsen) injection, for subcutaneous use Initial U.S. Approval: 202520250924